These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 31488052)

  • 1. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.
    Diaz-Ramos A; Eilbert W; Marquez D
    Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Case of Prolonged Recovery for Post-percutaneous Coronary Intervention (PCI) Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis in a 28-Year-Old.
    Petersen C; Gyabaah F; Sotelo J; Yohanna S; Deoker A
    Cureus; 2023 Sep; 15(9):e45180. PubMed ID: 37842482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Euglycemic Diabetic Ketoacidosis: Experience with 44 Patients and Comparison to Hyperglycemic Diabetic Ketoacidosis.
    Sell J; Haas NL; Korley FK; Cranford JA; Bassin BS
    West J Emerg Med; 2023 Nov; 24(6):1049-1055. PubMed ID: 38165186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Normal but Catastrophic" Euglycemic Diabetic Ketoacidosis Precipitated by Sodium-Glucose Cotransporter-2 Inhibitor Use: A Case Report.
    Sarno MJF; Hernandez DPF; Matulac MO
    Cureus; 2023 Nov; 15(11):e49236. PubMed ID: 38143642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetic Ketoacidosis as an Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Real World Insights.
    Baek HS; Jeong C; Yang Y; Lee J; Lee J; Lee SH; Cho JH; Sohn TS; Son HS; Yoon KH; Lee EY
    Diabetes Metab J; 2024 Jun; ():. PubMed ID: 38853537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Euglycemic diabetic ketoacidosis following traumatic brain injury.
    Jang SW; Lee H
    Am J Emerg Med; 2024 Mar; 77():232.e1-232.e3. PubMed ID: 38216364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes.
    Horii T; Oikawa Y; Atsuda K; Shimada A
    J Diabetes Investig; 2021 Sep; 12(9):1586-1593. PubMed ID: 33448127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normoglycemic diabetic ketoacidosis in a type 2 diabetes patient on dapagliflozin: A case report.
    Matli VVK; Fariduddin MM; Asafo-Agyei KO; Bansal N
    Clin Case Rep; 2021 Dec; 9(12):e05144. PubMed ID: 34917366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitor-Related Euglycemic Diabetic Ketoacidosis: A Case Series.
    Meier M; Ansong B; Awobusuyi D; Lee-Oyagha R; Lopez S
    J Pharm Pract; 2024 Aug; ():8971900241273169. PubMed ID: 39123293
    [No Abstract]   [Full Text] [Related]  

  • 10. Postoperative Euglycemic Ketoacidosis in Type 2 Diabetes Associated with Sodium-Glucose Cotransporter 2 Inhibitor: Insights Into Pathogenesis and Management Strategy.
    Chandrakumar HP; Chillumuntala S; Singh G; McFarlane SI
    Cureus; 2021 Jun; 13(6):e15533. PubMed ID: 34123681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the Benefits: A Case Study on the Complications of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors (Euglycemic Diabetic Ketoacidosis (DKA) and Takotsubo Cardiomyopathy).
    Sabanci R; Saaed M; Bandi A; Das K; Wilcox M
    Cureus; 2024 Feb; 16(2):e55068. PubMed ID: 38550506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter 2 Inhibitors: Clinical and Biochemical Characteristics of 29 Cases.
    Stamatiades GA; D'Silva P; Elahee M; Viana GM; Sideri-Gugger A; Majumdar SK
    Int J Endocrinol; 2023; 2023():6615624. PubMed ID: 37441367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Misleading Presentation: Chest Pain Masking Euglycemic Diabetic Ketoacidosis Possibly Induced by Empagliflozin.
    Tiwari K; Sharma NR; Pokhrel M; Basnet A; Kaplan M
    Cureus; 2023 Nov; 15(11):e49402. PubMed ID: 38149142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Euglycemic Ketoacidosis in a Patient without Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure.
    Miyazaki M; Nakano M; Takahashi H; Isaka Y; Hiura Y
    Am J Case Rep; 2024 Jul; 25():e943945. PubMed ID: 38985686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-Glucose Cotransporter 2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis: The Other Side of the Coin!
    Kamath SD; Kumar U; Shrivastava V
    Cureus; 2024 Apr; 16(4):e58341. PubMed ID: 38756291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Significance of Precise Diabetes Diagnosis: A Case of Euglycemic Diabetic Ketoacidosis Induced by the Introduction of Empagliflozin with Simultaneous Reduction of Insulin Dosage.
    Bińczyk W; Dróżdż O; Siudek B; Głuszczyk AM; Plizga JI; Grajnert FJ
    Eur J Case Rep Intern Med; 2024; 11(6):004567. PubMed ID: 38846667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 Precipitating Euglycaemic Diabetic Ketoacidosis with SGLT2 Inhibitor Use.
    Fang J; Genco M; Caskey RN
    Eur J Case Rep Intern Med; 2020; 7(11):001943. PubMed ID: 33194873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report: Diabetic ketoacidosis after co-administration of empagliflozin and probenecid.
    Martin WP; Reidy N; Low J; Ahern T
    Wellcome Open Res; 2023; 8():268. PubMed ID: 39114818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Euglycemic Diabetic Ketoacidosis and Sodium-Glucose Cotransporter-2 Inhibitors: A Focused Review of Pathophysiology, Risk Factors, and Triggers.
    Somagutta MR; Agadi K; Hange N; Jain MS; Batti E; Emuze BO; Amos-Arowoshegbe EO; Popescu S; Hanan S; Kumar VR; Pormento K
    Cureus; 2021 Mar; 13(3):e13665. PubMed ID: 33824816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-Glucose Cotransporter-2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis in a Type 2 Diabetic Patient.
    Haddadin R; Aboujamra D; Iraninezhad H
    Cureus; 2023 Dec; 15(12):e51184. PubMed ID: 38283482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.